Recurrent Ovarian Mixed Germ Cell Tumor with Unusual Malignant Transformation: a Case Report

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2019 Jan 12

PMID 30630520

Citations 3

Authors

Yi-Le Lee

Chiung-Ru Lai

Ming-Shyen Yen

Affiliations

Soon will be listed here.

Abstract

Background: The value of this report is the identification of late recurrence with an extremely unusual combination of malignant transformation. In particular, the retroconversion of immature to mature teratoma as well as a somatic-type malignant transformation were both observed postchemotherapeutically in our case.

Case Presentation: We report the case of a 20-year-old girl who completed fertility-sparing surgery and chemotherapy under the diagnosis of ovarian mixed germ cell tumor (immature teratoma and yolk sac tumor) and experienced subsequent recurrence 4 years after a second debulking surgery with a somatic type malignant transformation (teratoma with melanoma and leiomyosarcoma). Multiple metastases developed after a third debulking surgery, and the patient survived for 18 additional months.

Conclusions: Recurrent disease after repeated cytoreduction and chemotherapy hints a poor outcome despite a generally excellent long-term survival rate among ovarian germ cell malignancies. It is important for clinicians to distinguish those at risk of poorer outcomes and establish individualized postoperative surveillance. Fertility-compromising surgery may be considered in selected patients.

Citing Articles

Dysgerminomas: germ cell tumors exhibit high expression of PD-L1 and associated with high TILs and good prognosis.

Alwosaibai K, Alruwaii Z, Mashhour M, Almsned F, Asraf R, Alrsheedy W Sci Rep. 2024; 14(1):24191.

PMID: 39406772 PMC: 11480429. DOI: 10.1038/s41598-024-74192-z.

Nomograms to predict the prognosis in malignant ovarian germ cell tumors: a large cohort study.

Song Z, Wang Y, Zhou Y, Zhang D BMC Cancer. 2022; 22(1):257.

PMID: 35272629 PMC: 8908578. DOI: 10.1186/s12885-022-09324-7.

An Uncommon Recurrent Metastasis of Ovarian Immature Teratoma to the Small Bowel.

Al-Hazaimeh M, Jaradat M, El-Sadoni M, Smadi T, Shannaq R, Bani Hani O Case Rep Oncol. 2022; 14(3):1834-1840.

PMID: 35111017 PMC: 8787521. DOI: 10.1159/000520950.

References

Ben David Y, Weiss A, Shechtman L, Shalev E . Tumor chemoconversion following surgery, chemotherapy, and normalization of serum tumor markers in a woman with a mixed type germ cell ovarian tumor. Gynecol Oncol. 2002; 84(3):464-7. DOI: 10.1006/gyno.2001.6541. View

NORRIS H, Zirkin H, BENSON W . Immature (malignant) teratoma of the ovary: a clinical and pathologic study of 58 cases. Cancer. 1976; 37(5):2359-72. DOI: 10.1002/1097-0142(197605)37:5<2359::aid-cncr2820370528>3.0.co;2-q. View

Rezk Y, Sheinfeld J, Chi D . Prolonged survival following salvage surgery for chemorefractory ovarian immature teratoma: a case report and review of the literature. Gynecol Oncol. 2005; 96(3):883-7. DOI: 10.1016/j.ygyno.2004.11.035. View

Ulbright T . Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol. 2005; 18 Suppl 2:S61-79. DOI: 10.1038/modpathol.3800310. View

Poulos C, Cheng L, Zhang S, Gersell D, Ulbright T . Analysis of ovarian teratomas for isochromosome 12p: evidence supporting a dual histogenetic pathway for teratomatous elements. Mod Pathol. 2006; 19(6):766-71. DOI: 10.1038/modpathol.3800596. View

Smith H, Berwick M, Verschraegen C, Wiggins C, Lansing L, Muller C . Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006; 107(5):1075-85. DOI: 10.1097/01.AOG.0000216004.22588.ce. View

Patterson D, Rustin G . Controversies in the management of germ cell tumours of the ovary. Curr Opin Oncol. 2006; 18(5):500-6. DOI: 10.1097/01.cco.0000239891.44031.38. View

Murugaesu N, Schmid P, Dancey G, Agarwal R, Holden L, McNeish I . Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol. 2006; 24(30):4862-6. DOI: 10.1200/JCO.2006.06.2489. View

Li J, Yang W, Wu X . Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients. Gynecol Oncol. 2007; 105(3):769-75. DOI: 10.1016/j.ygyno.2007.02.032. View

10.

Gershenson D . Management of ovarian germ cell tumors. J Clin Oncol. 2007; 25(20):2938-43. DOI: 10.1200/JCO.2007.10.8738. View

11.

Einhorn L, Williams S, Chamness A, Brames M, Perkins S, Abonour R . High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007; 357(4):340-8. DOI: 10.1056/NEJMoa067749. View

12.

Pectasides D, Pectasides E, Kassanos D . Germ cell tumors of the ovary. Cancer Treat Rev. 2008; 34(5):427-41. DOI: 10.1016/j.ctrv.2008.02.002. View

13.

Hackethal A, Brueggmann D, Bohlmann M, Franke F, Tinneberg H, Munstedt K . Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data. Lancet Oncol. 2008; 9(12):1173-80. DOI: 10.1016/S1470-2045(08)70306-1. View

14.

Salani R, Backes F, Fung Kee Fung M, Holschneider C, Parker L, Bristow R . Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011; 204(6):466-78. DOI: 10.1016/j.ajog.2011.03.008. View

15.

Vicus D, Beiner M, Clarke B, Klachook S, Le L, Laframboise S . Ovarian immature teratoma: treatment and outcome in a single institutional cohort. Gynecol Oncol. 2011; 123(1):50-3. DOI: 10.1016/j.ygyno.2011.06.037. View

16.

Richie J . Preclinical and clinical activity of sunitinib in patients with Cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian urologic oncology group/German testicular cancer study group cooperative study. J Urol. 2013; 189(2):533-4. DOI: 10.1016/j.juro.2012.10.091. View

17.

Jain A, Brames M, Vaughn D, Einhorn L . Phase II clinical trial of oxaliplatin and bevacizumab in refractory germ cell tumors. Am J Clin Oncol. 2013; 37(5):450-3. DOI: 10.1097/COC.0b013e31827de90d. View

18.

Kraggerud S, Hoei-Hansen C, Alagaratnam S, Skotheim R, Abeler V, Rajpert-De Meyts E . Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis. Endocr Rev. 2013; 34(3):339-76. PMC: 3787935. DOI: 10.1210/er.2012-1045. View

19.

Matei D, Brown J, Frazier L . Updates in the management of ovarian germ cell tumors. Am Soc Clin Oncol Educ Book. 2013; . DOI: 10.14694/EdBook_AM.2013.33.e210. View

20.

Vazquez I, Rustin G . Current controversies in the management of germ cell ovarian tumours. Curr Opin Oncol. 2013; 25(5):539-45. DOI: 10.1097/01.cco.0000432609.39293.77. View